PotentantibacterialagentwhichdisruptslipidbilayersynthesisthroughinhibitionofLpxC(IC50=1.1nMinPseudomonasaeruginosa);effectiveagainstarangeofgramnegativebacteria.
SoldforresearchpurposesunderagreementfromPfizerInc.
| M.Wt | 412.43 |
| Formula | C18H21FN2O6S |
| Storage | Storeat-20°C |
| Purity | ≥98%(HPLC) |
| CASNumber | 1312473-63-4 |
| PubChemID | 56964907 |
| InChIKey | DNVUWHWBCMGQLU-GOSISDBHSA-N |
| Smiles | O=C1N(CC[C@]([S@@](C)(=O)=O)(C)C(NO)=O)C=CC(C2=CC=C(OC)C=C2F)=C1 |
Thetechnicaldataprovidedaboveisforguidanceonly.ForbatchspecificdatarefertotheCertificateofAnalysis.
AllTocrisproductsareintendedforlaboratoryresearchuseonly.
| Solvent | MaxConc.mg/mL | MaxConc.mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 41.24 | 100 |
Thefollowingdataisbasedontheproductmolecularweight412.43.Batchspecificmolecularweightsmayvaryfrombatchtobatchduetosolventofhydration,whichwillaffectthesolventvolumesrequiredtopreparestocksolutions.
| Concentration/SolventVolume/Mass | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1mM | 2.42mL | 12.12mL | 24.25mL |
| 5mM | 0.48mL | 2.42mL | 4.85mL |
| 10mM | 0.24mL | 1.21mL | 2.42mL |
| 50mM | 0.05mL | 0.24mL | 0.48mL |



